Phase I/II study of treatment of stage IV breast cancer with OKT3 x trastuzumab-armed activated T cells

Clin Breast Cancer. 2003 Aug;4(3):212-7. doi: 10.3816/cbc.2003.n.028.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy*
  • Female
  • Humans
  • Muromonab-CD3 / administration & dosage
  • Muromonab-CD3 / therapeutic use*
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Patient Selection
  • Receptor, ErbB-2 / analysis
  • Research Design
  • T-Lymphocytes*
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Muromonab-CD3
  • Receptor, ErbB-2
  • Trastuzumab